Clinical Trial Update: DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01] [Phase 2]

View source ↗

Summary

Phase 2 trial Destiny-Gastric01 evaluating DS-8201a (trastuuzumab deruxtecan) in HER2-expressing gastric cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• DS-8201a (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Neoplasm, Gastrointestinal | Phase 2 | Status: COMPLETED | Results posted: 2020-11-27